EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Lukas Biomedical Inc. (6814) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Lukas Biomedical Inc. TWD 3.84, price TWD 18.90, upside -79.7%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN TW0006814007

LB Thin data Sep 24, 2026

Lukas Biomedical Inc.

6814 · TWO

Weakest SetupStrongly overvalued and low quality.

!Fair value 3.84 TWD · Strongly overvalued (−80%)
!Quality 35/100
!Weak Growth (revenue 5y −0.2 %/yr)
!Loss-making · -47.7% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (2/10)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Watch Lukas Biomedical Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

31.70 TWD 17.30 TWD Fair Value 3.84 TWD Dec 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.

How to read this chart

10‑month range 17.30 TWD – 31.70 TWD · fair‑value band 2.87 TWD – 5.74 TWD · the 18.90 TWD price screens above the 3.84 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.

Follow Lukas Biomedical in your weekly email

Every Wednesday you see whether Lukas Biomedical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments.

Show more

Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distributes immune cell therapy culture technology; and leases building equipment. In addition, the company involved in the new immune cell research and development, new product development, clinical trials, and production of cell reagents; and provision of brand management and medical management services. Lukas Biomedical Inc. was founded in 2002 and is based in New Taipei City, Taiwan.

Stock analysis

Lukas Biomedical Inc. (6814) currently trades at 18.90 TWD, while our model-based Fair Value estimate is 3.84 TWD, implying the stock looks roughly 392.1% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 2.87 TWD (bear) to 5.74 TWD (bull), the price of 18.90 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Lukas Biomedical Inc. reported revenue of 179M TWD in FY2025 versus 158M TWD in FY2021, a compound +3.3%/yr. Reported net income was −85.6M TWD in FY2025.

Key figures

Market cap 1.0B TWD (≈ $32.3M) · P/S ratio 5.73 · EPS (TTM) −2.05 TWD · Net margin −47.7% · Return on equity −30.3% · Return on assets (EBIT) −13.3% · Operating margin −43.7% · Revenue (TTM) 179M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −80%, 6814 screens richer than that median.

Fair Value models

Bear 2.87 TWD Fair Value 3.84 TWD Bull 5.74 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 2.87 TWD 3.84 TWD 5.74 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 2.87 TWD 3.84 TWD 5.74 TWD 54

Open the full fair value analysis →

Notify me when 6814 reaches fair value

Put 6814 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 35/100

Of which business quality 35 · Market factors (momentum, volatility) 27

Profitability 14
Margins and returns on capital today
Quality Growth 33
Are margins and returns improving?
Cashflow 5
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 95
Disciplined investing over empire-building
Low Volatility 69
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 32
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 4/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3.6% (2020) → −45.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6814 screens 392% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Lukas Biomedical Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −79% · Bottom 25%
Profitability
Return on assets −11% · Below median
Net margin (TTM) −48% · Bottom 25%
Operating margin (TTM) −44% · Bottom 25%
Growth and dividend
Revenue growth −1% · Below median
Balance sheet
Debt / equity 0.20× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.13× · Cheapest 25%
P/S (TTM) 0.18× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)90 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lukas Biomedical Inc. · Fair Value
3.84 TWD −392%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Lukas Biomedical Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6814

Frequently asked questions

Is Lukas Biomedical Inc. (6814) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 3.84 TWD versus a price of 18.90 TWD, about −80% upside (overvalued).
What is the fair value of 6814?
Our model-based fair value for Lukas Biomedical Inc. is 3.84 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 18.90 TWD.
What is the quality score of 6814?
Lukas Biomedical Inc. has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lukas Biomedical Inc. (6814)?
Our model-based price target is the fair value of 3.84 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 2.87 TWD, optimistic scenario 5.74 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Lukas Biomedical Inc. stock forecast for 2026?
Our models put fair value at 3.84 TWD, about −80% upside versus a price of 18.90 TWD (overvalued). Cautious scenario 2.87 TWD, optimistic scenario 5.74 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Lukas Biomedical Inc. (6814)?
Lukas Biomedical Inc. reported trailing-twelve-month revenue of about 179M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Lukas Biomedical Inc. (6814)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lukas Biomedical Inc. it is 3.84 TWD per share (as of Sep 24, 2026), against a price of 18.90 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Lukas Biomedical Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6814 trades above its calculated fair value: price 18.90 TWD, fair value 3.84 TWD, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6814?
No. The price is what the market pays today (18.90 TWD); the fair value is what the company's own numbers justify (3.84 TWD). For Lukas Biomedical Inc. the two are 15.06 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Lukas Biomedical Inc. worth?
The market values Lukas Biomedical Inc. at about 1.0B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 18.90 TWD; our models calculate a fair value of 3.84 TWD per share.
What do the bullish and bearish scenarios say about 6814?
Our models span a range for Lukas Biomedical Inc.: cautious scenario 2.87 TWD, base 3.84 TWD, optimistic 5.74 TWD per share (as of Sep 24, 2026, price 18.90 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lukas Biomedical Inc. (6814)?
Balance-sheet figures for Lukas Biomedical Inc. (as of Sep 24, 2026): return on equity −30.3%, debt of 0.20 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
Which stocks are comparable to Lukas Biomedical Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lukas Biomedical Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price 18.90 TWD, calculated fair value 3.84 TWD (−80%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6814 calculated?
We run Lukas Biomedical Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3.84 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Lukas Biomedical Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lukas Biomedical Inc. (6814)?
The closing price on Sep 24, 2026 was 18.90 TWD. Our model-based fair value is 3.84 TWD, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lukas Biomedical Inc. right now?
The price sits above even our optimistic bull case (5.74 TWD). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2.87 TWD to 5.74 TWD) leaves room in how you read the outcome.

Key figures of Lukas Biomedical Inc.

How large is the market capitalisation of Lukas Biomedical Inc. (6814)?
The market capitalisation of Lukas Biomedical Inc. is 1.0B TWD (≈ $32.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lukas Biomedical Inc. (6814)?
The price-to-sales ratio of Lukas Biomedical Inc. is 5.73 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lukas Biomedical Inc. (6814)?
Earnings per share at Lukas Biomedical Inc. are −2.05 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lukas Biomedical Inc. (6814)?
The net margin of Lukas Biomedical Inc. is −47.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lukas Biomedical Inc. (6814)?
The return on equity (ROE) of Lukas Biomedical Inc. is −30.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lukas Biomedical Inc. (6814)?
On an EBIT basis the return on assets of Lukas Biomedical Inc. is −13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lukas Biomedical Inc. (6814)?
The operating margin of Lukas Biomedical Inc. is −43.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lukas Biomedical Inc. (6814)?
Revenue at Lukas Biomedical Inc. is growing −0.9% versus a year earlier (3y avg −1.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Lukas Biomedical Inc. (6814) generate?
The free cash flow of Lukas Biomedical Inc. is −69.9M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lukas Biomedical Inc. (6814) carry?
The net debt of Lukas Biomedical Inc. is 88.7M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Lukas Biomedical Inc. in the live analysis

One click puts Lukas Biomedical Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.